Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Operations of Simcere’s Latest Acquisition Remain Shut Down

publication date: Apr 5, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharmaceutical Group (先声药业)reported that a recent acquisition, Jiangsu Yanshen Biological Technology, committed fraud with respect to its human-use rabies vaccine before Simcere bought its controlling interest in October 2009. As soon as Simcere found out about the problem, it urged Jiangsu Yanshen’s board to cease operations and review the company’s quality control. It has complied with the official investigation into the situation. More details...

Stock Symbol: (NYSE: SCR)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners